Quantitation and Dynamics of Dc-Sign Microdomains on the Cell Surface  by Liu, Ping et al.
Tuesday , March 8, 2011 347a1880-Plat
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DC-SIGN, a dendritic cell (DC)-specific C-type lectin that binds many dif-
ferent pathogens, is a receptor for HIV-1 and promotes subsequent infection
of T cells. Our previous study demonstrated that DC-SIGN forms sub-mi-
cron scale domains on the surface of immature DCs as well as cell lines
that ectopically express DC-SIGN. In this study, we investigated the occu-
pancy and dynamics of DC-SIGN surface domains. First, we developed
a single molecule approach, based on total internal reflection fluorescence
(TIRF) microscopy, to examine the number of DC-SIGN molecules in a sin-
gle domain. By comparing the brightness of a single fluorophore to the total
brightness of a fluorescently-labeled DC-SIGN domain, we show that the
number of DC-SIGN proteins in a domain ranges from a few to over hun-
dred molecules. The size of each domain, as measured from the full-width
half-maximum (FWHM) of a Gaussian fit of the emission profile of a do-
main, varies from the diffraction limit to micron scale. Second, scanning
fluorescence correlation spectroscopy (sFCS) and fluorescence recovery af-
ter photobleaching (FRAP) were carried out to investigate the mobility of
DC-SIGN in a domain, both of which showed that DC-SIGN is highly im-
mobile. This was corroborated by single particle tracking of quantum dots
attached to DC-SIGN molecules within a domain. By contrast, photobleach-
ing of a lipid modified-fluorescent protein (mRFP) in a DC-SIGN domain
area showed full recovery similar to that outside of the domain, indicating
that lipids inside the DC-SIGN domain are highly mobile and and can
freely exchange with the surrounding membrane. Finally, a deletion muta-
tion study of DC-SIGN was carried out to further investigate which moiety
of DC-SIGN facilitates surface domain formation. Supported by NIH
GM41402.Platform AI: Acetylcholine Receptors & Channel
Regulation
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Macrocyclic spiroimine phycotoxins belong to an emerging class of chemical
agents associated with marine algal blooms and shellfish toxicity. [1] Represen-
tative members of this family are gymnodimines, spirolides, pinnatoxins, pter-
iatoxins, and spiro-prorocentrimine. Gymnodimine A and 13-desmethyl
spirolide C have been shown to be potent antagonists of nicotinic acetylcholine
receptor (nAChR), and have prompted the development of new tools to detect
these spiroimine toxins in shellfish and for the design of novel drugs. [2,3] Very
recently, crystal structures of Acetylcholine Binding Protein complexed with
gymnodimine A and 13-desmethyl spirolide C were solved, thus providing
insight into the orientation and the conformation adopted by these ligands in
the binding pocket and their interactions with neighbouring amino-acid
residues. [3]
In this work we have explored the interaction of several members of spiroi-
mine toxins family with different nAChR subtypes. Given the lack of gen-
eral methods for flexible docking of macrocyclic ligands, we have developed
a two-step, general approach to circumvent this problem, and applied it spe-
cifically to the docking of macrocyclic spiroimines on nAChRs. Subsequent
molecular dynamics studies of the resulting receptor-ligand complexes al-
lowed us to identify the key interactions responsible for the high affinity
and target selectivity experimentally determined for some of these phycotox-
ins.
[1] J. Molgo´, E. Girard, E. Benoit, "The cyclic imines: an insight into this
emerging group of bioactive marine toxins" in: Phycotoxins: Chemistry and
Biochemistry (Eds.: Y. H. Hui, L. M. Botana), Blackwell Publishing, 2007,
pp. 319-355.[2] R. Kharrat, D. Servent, E. Girard, G. Ouanounou, M. Amar, R. Marrouchi,
E. Benoit, J. Molgo´, J. Neurochem., 2008 107, 952-963.
[3] Y. Bourne, Z. Radic, R. Araoz, T. T. Talley, E. Benoit, D. Servent,
P. Taylor, J. Molgo´, P. Marchot, Proc. Natl. Acad. Sci. USA, 2010, 107,
6076-6081.1882-Plat
Potentiation of the Human a7 Acetylcholine Receptor: A Single-Channel
Study
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Allosteric modulation of neuronal nicotinic acetylcholine receptors by exog-
enous ligands is a promising strategy for the treatment of several neurolog-
ical disorders including Alzheimer’s disease and Schizophrenia. To gain
insight into the molecular mechanisms underlying allosteric modulation,
we have examined with single-channel recordings, the potentiation of hu-
man a7 nicotinic acetylcholine receptors by both a Type I, and a Type
II positive allosteric modulator (PAM). Dwell time analysis reveals that
both NS-1738 (Type I PAM) and PNU-120596 (PNU; Type II PAM)
lead to prolonged openings in the presence of agonist. While co-application
of NS-1738 with agonist results in the appearance of a single new compo-
nent in open time histograms,
co-application of PNU leads
to two additional compo-
nents, the longest of which
coalesce into clusters of
openings whose frequency
and duration depend on
PNU concentration. At satu-
rating concentrations of
PNU these clusters last as
long as several minutes, representing a ~10,000-100,000 fold prolongation
of the notoriously brief a7 openings. The differences between Type I and
Type II potentiation evident at the microscopic/single-channel level will
be discussed in the context of the variable phenotypes previously character-
ized at the macroscopic/whole cell level.1883-Plat
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Acetylcholine receptor-channels (AChRs) mediate fast chemical transmis-
sion at the synapse. Agonist molecules, such as acetylcholine and nicotine,
bind at two transmitter binding sites and trigger the channel to switch from
a closed to an open conformation. At the synaptic cleft, acetylcholine is hy-
drolyzed by acetylcholinesterase to acetate and choline. Replacing an ester
acetyl group by a hydroxyl group (from acetylcholine to choline) decreases
the resting affinity by ~50-fold and efficacy by ~600-fold. To understand the
action of these ligands and to design novel drugs, it is essential to measure
both affinity and efficacy of agonist derivatives using wild type and binding-
site mutated AChRs. A technical limitation is that agonists block the chan-
nel. Thus, experiments at high agonist concentrations, required due to a low
affinity agonist or mutant, are difficult at 100 mV membrane potential. Us-
ing a background mutation and depolarization, we have developed an ap-
proach to measure AChR single-channel currents activated by various
agonists without channel block even at concentrations >140 mM. Using
this method, we have directly measured the efficacy of several derivatives
of choline on the mouse neuromuscular AChR. Replacing the hydroxyl
group of choline with different substituents, such as hydrogen, chloride,
methyl, or amine, increases the relative efficacy by 2-9 fold. Extending
the ethyl hydroxide tail of choline to propyl and butyl hydroxide also pro-
duces more efficacious agonists, by 4.8 and 25-fold, respectively. Perhaps
the neuromuscular AChR has specifically evolved to be poorly activated
by choline. Our findings reveal the amount of the energy available for
AChR conformational change from different agonists. We are searching
for the site(s) in the AChR that make choline such a low-efficacy agonist.
Supported by NIH (NS-23513, NS-064969).
